A panel of three experts, led by Dr. Brian Slomovitz of Sylvester Comprehensive Cancer Center, University of Miami Health System, discussed the expanded role of PARP inhibitors and how the new targeted agents, niraparib, olaparib, and rucaparib, are setting a new paradigm in the treatment of advanced ovarian cancer. Topics covered included a look at three landmark trials from ESMO and how they've influenced treatment regimens, incorporating BRCA and HRD testing on patients, and sequencing PARP inhibitors with and without bevacizumab as part of treatment.
View Roundtable

James Berenson, MD, Shaji Kumar, MD, and Ruben Niesvizky, MD discuss the latest treatment trends and clinical advances in multiple myeloma including: Use of quadruplets vs. triplets, Current role of stem cell transplant, Role of maintenance therapy, Monitoring of Multiple Myeloma, Role of precision medicine
View Roundtable